Article Text

Download PDFPDF
  1. Shahd Hamid1,2,
  2. Mariyam Saviour1,2,
  3. Kerry Much1,
  4. Liene Elsone1,
  5. Maneesh Bhojak1,2,
  6. Anu Jacob1,2
  1. 1 The Walton Centre
  2. 2 University of Liverpool


Background Antibodies to myelin oligodendrocyte glycoprotein (MOG) are being increasingly detected in patients with non-MS demyelination many of whom have the neuromyelitis optica spectrum disorders (NMOSD) phenotype. Cortical involvement or seizures are rare in AQP4 IgG NMO. Having encountered one MOG IgG+ve patient with seizures we systematically reviewed all our patients.

Method Retrospective review of the clinical and MRI data of all MOG IgG +ve cases (n=28) and 100 patients with AQP4 IgG+ve NMOSD for seizures and cortical lesions.

Results Only 1/100 NMOSD with AQP4 IgG had seizures (1%)-a 43-year old woman with epilepsy, her first seizure 5 years before the onset of NMOSD. Brain MRI was normal. 4/28 patients with MOG IgG had seizures (14%) that occurred along with an episode of demyelination. All 4 had cortical lesions and relapsing demyelination and are on immunosuppressants. 3 continue on antiepileptic drugs.

Conclusion Patients with MOG IgG associated disease are more likely to have seizures (P<0.008, Fisher's test) and cortical MRI changes compared to AQP4IgG +ve cases. This may further support the view that the two are different diseases.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.